Clinical Trials


Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women

This study has been completed
Boehringer Ingelheim

Information provided by (Responsible Party)
Boehringer Ingelheim Identifier

First received: July 2, 2014
Last updated: July 11, 2014
Last Verified: July 2014
History of Changes


The primary objective of the study was to evaluate the efficacy of nevirapine versus ZDV+3TC (Zidovudine + Lamivudine), when administered in labor and again at postdelivery, in reducing peripartum mother to child transmission of HIV (Human Immunodeficiency Virus).

The secondary objective was to assess the overall HIV transmission rate between the 2 groups (intrauterine, intrapartum and postpartum up to 6 weeks) as well as to explore the relationship between infection and timing of maternal dose relative to birth, infant feeding method, maternal peripheral blood viral load, and other potential risk factors for transmission.

Following the introduction of the second and third Amendments to the Protocol, 2 substudies were added. The objectives of these substudies were to evaluate the frequency of resistance-conferring mutations to nevirapine (Amendment 2) and to ZDV+3TC (Amendment 3); to determine whether there was a reversion of any resistant virus to the wild type; and to determine if the resistant virus was transmitted from the mother to the child.

Condition Intervention Phase
HIV Infections

Drug : Nevirapine
Drug : Zidovudine (ZDV)
Drug : Lamivudine (3TC)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Randomised Open Label Clinical Trial to Determine the Efficacy of Nevirapine, Compared With a Combination of ZDV + 3TC, in Decreasing the Peripartum Mother to Child Transmission of HIV. Women, Who Present After 38 Weeks Gestation or in Labour After 35 Weeks Gestation and Who Are Anti-retroviral Naive, Will be Included.

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures

  • Incidence of HIV transmission from a HIV positive mother to her exposed infant during the intrapartum and early postpartum period [ Time Frame: Day 28, 42 and 56-84 ]
Secondary Outcome Measures:
  • Overall HIV transmission rate (including intrauterine, intrapartum and postpartum) [ Time Frame: up to 84 days ]
  • Time to infection [ Time Frame: up to 84 days ]
  • Relationship between infection and timing of maternal dose relative to birth [ Time Frame: up to 84 days ]
  • Relationship between infection and infant feeding method [ Time Frame: up to 84 days ]
  • Relationship between infection and maternal peripheral blood viral load [ Time Frame: Day 0 and 28 ]
  • Relationship between infection and other potential risk factors [ Time Frame: up to 84 days ]
  • Number of patients with adverse events [ Time Frame: up to 84 days ]

Enrollment: 2648
Study Start Date: April 1999
Primary Completion Date: January 2001 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Nevirapine
Mother: two doses, Infant: one dose
Drug: Nevirapine
Active Comparator: Zidovudine (ZDV) + Lamivudine (3TC)

Drug: Zidovudine (ZDV)
Drug: Lamivudine (3TC)


Ages Eligible for Study: Child, Adult, Senior  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria:

  • Pregnant women who present after 38 weeks gestation or in labour after 35 weeks gestation who are tested HIV positive. Estimated gestational age will be determined by one or more of the following:
    • Reliable menstrual history, which corresponds with uterine size
    • Physical examination
    • Estimated fetal weight
  • A consent form for the mother and neonate will be signed by either the mother or the guardian prior to inclusion

Exclusion Criteria:
  • Mothers who have taken any antiretrovirals in the last 12 months
  • Mothers who are not able to take oral medication
  • Mothers who present with ARDS (acute respiratory distress syndrome), septic shock or eclampsia
  • Mothers presenting in discomfort, i.e. regular painful uterine contractions, or other factors that may contribute to her not being able to understand and sign the informed consent for HIV testing and study participation
  • Use of another investigational drug or concurrent participation in another investigational protocol during the current pregnancy
  • Unwillingness or inability to reasonably comply with the protocol (i.e., mother and neonate/infant could not be followed for the full 6 weeks of the trial)
  • Grade 4 SGPT (Serum glutamate pyruvate transaminase) (>10 times the upper limit of normal value), if known prior to delivery
  • A recent history (6 months preceding the study) or current evidence of drug abuse and/or alcoholism
  • Mothers with fetuses with anomalies incompatible with life, if known prior to delivery
  • Decision to deliver the infant by elective Cesarean section
  • Amniocentesis was indicated
  • Infants with severe growth retardation diagnosed before birth

  • Infants who fall into the following groups will not receive treatment, but the mother-infant pair will remain in the trial
  • Infants with malformations incompatible with life
  • Life-threatening perinatal conditions which do not allow oral therapy (e.g., sepsis)

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02181933

Sponsors and Collaborators

Boehringer Ingelheim
More Information

More Information

Responsible Party: Boehringer Ingelheim Identifier: NCT02181933   History of Changes  
Other Study ID Numbers: 1100.1287  
Study First Received: July 2, 2014  
Last Updated: July 11, 2014  

Additional relevant MeSH terms:
HIV Infections
Nevirapine processed this data on January 28, 2020
This information is provided by